Artículos por temáticas

Diffusion tensor imaging measures of normal appearing white matter in patients who are aging, or have amnestic mild cognitive impairment, or Alzheimer's disease

Wang JH, Lv PY, Wang HB, Li ZL, Li N, Sun ZY, Zhao BH, Huang Y.

J Clin Neurosci. 2013 Aug;20(8):1089-94. doi: 10.1016/j.jocn.2012.09.025. Epub 2013 Jun 17.

Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism

Haight TJ, Landau SM, Carmichael O, Schwarz C, DeCarli C, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

JAMA Neurol. 2013 Aug;70(8):1039-45. doi: 10.1001/jamaneurol.2013.1878.

Inflammatory proteins in plasma are associated with severity of Alzheimer's disease

Leung R, Proitsi P, Simmons A, Lunnon K, Güntert A, Kronenberg D, Pritchard M, Tsolaki M, Mecocci P, Kloszewska I, Vellas B, Soininen H, Wahlund LO, Lovestone S.

PLoS One. 2013 Jun 10;8(6):e64971. doi: 10.1371/journal.pone.0064971. Print 2013.

Ushering in the study and treatment of preclinical Alzheimer disease

Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT, Caselli RJ, Tariot PN, Reiman EM.

Nat Rev Neurol. 2013 Jul;9(7):371-81. doi: 10.1038/nrneurol.2013.107. Epub 2013 Jun 11.

Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly

Randall C, Mosconi L, de Leon M, Glodzik L.

Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170.

APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease

Reinvang I, Espeseth T, Westlye LT.

Neurosci Biobehav Rev. 2013 Sep;37(8):1322-35. doi: 10.1016/j.neubiorev.2013.05.006. Epub 2013 May 20.

Mild cognitive impairment due to Alzheimer disease in the community

Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA, Weigand S, Weiner M, Wiste H, Jack CR Jr.

Ann Neurol. 2013 Aug;74(2):199-208. doi: 10.1002/ana.23931.

Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study

Damian M, Hausner L, Jekel K, Richter M, Froelich L, Almkvist O, Boada M, Bullock R, De Deyn PP, Frisoni GB, Hampel H, Jones RW, Kehoe P, Lenoir H, Minthon L, Olde Rikkert MG, Rodriguez G, Scheltens P

Dement Geriatr Cogn Disord. 2013;36(1-2):1-19. doi: 10.1159/000348354. Epub 2013 May 3.

[The potential role for sphingolipids in neuropathogenesis of Alzheimer's disease]

Alesenko AV.

Biomed Khim. 2013 Jan-Feb;59(1):25-50.

Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI

Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, Vemuri P, Senjem ML, Jordan L, Jack CR Jr, Knopman D, Petersen RC.

Neurology. 2013 Jun 4;80(23):2130-7. doi: 10.1212/WNL.0b013e318295d6cf. Epub 2013 May 3.

Applying the IWG research criteria in clinical practice: feasibility and ethical issues

Molinuevo JL, Rami L.

Med Clin North Am. 2013 May;97(3):477-84. doi: 10.1016/j.mcna.2012.12.018. Epub 2013 Feb 1.

Clinical trials in predementia stages of Alzheimer disease

Pillai JA, Cummings JL.

Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1.

Cerebrospinal fluid levels of phosphorylated tau and Aβ1-38/Aβ1-40/Aβ1-42 in Alzheimer's disease with PS1 mutations

Ikeda M, Yonemura K, Kakuda S, Tashiro Y, Fujita Y, Takai E, Hashimoto Y, Makioka K, Furuta N, Ishiguro K, Maruki R, Yoshida J, Miyaguchi O, Tsukie T, Kuwano R, Yamazaki T, Yamaguchi H, Amari M, Takat

Amyloid. 2013 Jun;20(2):107-12. doi: 10.3109/13506129.2013.790810. Epub 2013 May 2.

Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease

Schmitt A, Falkai P.

Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):271-2. doi: 10.1007/s00406-013-0409-0.